NZ737666A - Antibody binding to fcrn for treating autoimmune diseases - Google Patents

Antibody binding to fcrn for treating autoimmune diseases

Info

Publication number
NZ737666A
NZ737666A NZ737666A NZ73766615A NZ737666A NZ 737666 A NZ737666 A NZ 737666A NZ 737666 A NZ737666 A NZ 737666A NZ 73766615 A NZ73766615 A NZ 73766615A NZ 737666 A NZ737666 A NZ 737666A
Authority
NZ
New Zealand
Prior art keywords
fcrn
antibody
autoimmune diseases
receptor
antibody binding
Prior art date
Application number
NZ737666A
Other languages
English (en)
Inventor
Sung Wuk Kim
Seung Kook Park
Jae Kap Jeong
Hyea Kyung Ahn
Min Sun Kim
Eun Sun Kim
Hae-Young Yong
Dongok Shin
Yeon Jung Song
Tae Hyoung Yoo
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Publication of NZ737666A publication Critical patent/NZ737666A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
NZ737666A 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases NZ737666A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461986742P 2014-04-30 2014-04-30
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Publications (1)

Publication Number Publication Date
NZ737666A true NZ737666A (en) 2018-10-26

Family

ID=54358928

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ737666A NZ737666A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ726089A NZ726089A (en) 2014-04-30 2015-04-30 Antibody binding to fcrn for treating autoimmune diseases

Country Status (21)

Country Link
US (6) US10544226B2 (cg-RX-API-DMAC7.html)
EP (2) EP3137504B1 (cg-RX-API-DMAC7.html)
JP (1) JP6449441B2 (cg-RX-API-DMAC7.html)
KR (2) KR101889466B1 (cg-RX-API-DMAC7.html)
CN (2) CN106459215B (cg-RX-API-DMAC7.html)
AU (2) AU2015253915B2 (cg-RX-API-DMAC7.html)
CA (2) CA3095295C (cg-RX-API-DMAC7.html)
DK (1) DK3137504T5 (cg-RX-API-DMAC7.html)
EA (1) EA038470B1 (cg-RX-API-DMAC7.html)
ES (1) ES2952583T3 (cg-RX-API-DMAC7.html)
FI (1) FI3137504T3 (cg-RX-API-DMAC7.html)
HU (1) HUE062403T2 (cg-RX-API-DMAC7.html)
IL (2) IL248159B (cg-RX-API-DMAC7.html)
MX (2) MX382284B (cg-RX-API-DMAC7.html)
NZ (2) NZ737666A (cg-RX-API-DMAC7.html)
PL (1) PL3137504T3 (cg-RX-API-DMAC7.html)
PT (1) PT3137504T (cg-RX-API-DMAC7.html)
RS (1) RS64542B1 (cg-RX-API-DMAC7.html)
SA (1) SA516380194B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201608208VA (cg-RX-API-DMAC7.html)
WO (1) WO2015167293A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106957365B (zh) * 2016-01-11 2021-03-16 上海交通大学 一种单克隆抗体FnAb8及其应用
AU2017257680A1 (en) * 2016-04-25 2018-12-06 Syntimmune, Inc. Humanized affinity matured anti-FcRn antibodies
IL302288B2 (en) * 2016-07-29 2025-09-01 Momenta Pharmaceuticals Inc FCRN antibodies and methods of using them
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Ｇｕａｎｇｚｈｏｕ Ｈａｎｆａｎｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．，Ｌｔｄ． シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
BR112019026694A2 (pt) * 2017-06-15 2020-06-23 UCB Biopharma SRL Método para o tratamento da trombocitopenia imune
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
KR20210078517A (ko) 2018-10-16 2021-06-28 유씨비 바이오파마 에스알엘 중증근무력증의 치료 방법
MX2021005323A (es) * 2018-11-06 2021-08-24 Immunovant Sciences Gmbh Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn.
GB2589049C (en) * 2019-04-11 2024-02-21 argenx BV Anti-IgE antibodies
IL292889A (en) * 2019-11-19 2022-07-01 Immunovant Sciences Gmbh Methods for the treatment of warm autoimmune hemolytic anemia using anti-fcrn antibodies
CN114341184B (zh) * 2020-02-10 2023-04-04 北京拓界生物医药科技有限公司 抗FcRn抗体、其抗原结合片段及其医药用途
IL299150A (en) * 2020-06-29 2023-02-01 Hanall Biopharma Co Ltd Formulation for anti-fcrn antibody
JP7765457B2 (ja) * 2020-08-06 2025-11-06 ステレクシス セラピューティクス，エルエルシー Ｉｌ－８抗体及びその使用方法
CN113484526B (zh) * 2021-08-11 2024-08-23 上海迈晋生物医药科技有限公司 一种抗FcRn抗体或其抗原结合片段生物学活性的检测方法
KR20240036076A (ko) * 2021-08-13 2024-03-19 스테이드슨 (베이징) 바이오팔마슈티칼스 캄퍼니 리미티드 Fcrn을 특이적으로 인식하는 항체 및 이의 용도
US20250026814A1 (en) * 2021-11-16 2025-01-23 The University Of Chicago Polypeptides for detection and treatment of coronavirus infection
CN114573698B (zh) * 2022-03-16 2023-01-06 沈阳三生制药有限责任公司 一种FcRn抗原结合蛋白及其制备方法和应用
CA3254741A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. ANTI-FCRN ANTIBODY OR ANTIGEN-BINDING FRAGMENT OF FCRN EXHIBITING IMPROVED STABILITY
WO2023235679A1 (en) 2022-05-30 2023-12-07 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
JP2025526384A (ja) * 2022-07-27 2025-08-13 アブリンクス エン．ヴェー． 新生児型Ｆｃ受容体の特異的エピトープに結合するポリペプチド
EP4584295A1 (en) 2022-09-06 2025-07-16 Immunovant Sciences GmbH Methods of treating chronic inflammatory demyelinating polyneuropathy using anti-fcrn antibodies
KR20250079929A (ko) 2022-09-06 2025-06-04 이뮤노반트 사이언시스 게엠베하 항-FcRN 항체를 이용한 그레이브스병의 치료 방법
KR20250156749A (ko) 2023-03-08 2025-11-03 이뮤노반트 사이언시스 게엠베하 폴리소르베이트 부형제를 포함하는 고농도 단백질 제제 및 이의 제조 방법
AR133188A1 (es) 2023-07-05 2025-09-03 Ablynx Nv ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG
TW202525850A (zh) 2023-07-16 2025-07-01 比利時商阿根思公司 治療慢性發炎性脫髓鞘多發性神經病變之方法
WO2025093717A1 (en) 2023-10-31 2025-05-08 Immunovant Sciences Gmbh Methods of improving anti-fcrn therapies
WO2025099576A1 (en) 2023-11-06 2025-05-15 Momenta Pharmaceuticals, Inc. Compositions and methods for treating rheumatoid arthritis
WO2025163617A1 (en) 2024-02-04 2025-08-07 Momenta Pharmaceuticals, Inc. Compositions and methods for treating sjögren's disease
CN119490588A (zh) * 2024-10-17 2025-02-21 广州康盛生物科技股份有限公司 一种抗人FcRn的VHH抗体及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714350A (en) * 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US20050079169A1 (en) * 2003-08-08 2005-04-14 Balthasar Joseph P. Anti-FcRn antibodies for treatment of auto/allo immune conditions
US7662928B2 (en) * 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
US20100266530A1 (en) * 2005-04-29 2010-10-21 The Jackson Laboratory FcRN ANTIBODIES AND USES THEREOF
CA2637929A1 (en) * 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
SI2602323T1 (en) 2007-06-01 2018-05-31 Open Monoclonal Technology, Inc. Compositions and procedures for inhibiting endogenous immunoglobin gene and the formation of transgenic human idiopathic antibodies
CA2722082C (en) * 2008-04-25 2021-11-09 Christopher Tenhoor Fc receptor binding proteins
PH12013502378A1 (en) * 2011-06-02 2014-01-06 Dyax Corp Fc RECEPTOR BINDING PROTEINS
KR20130071961A (ko) 2011-12-21 2013-07-01 한올바이오파마주식회사 ＦｃＲｎ 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
GB201208370D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
KR102282134B1 (ko) 2013-04-29 2021-07-27 에프. 호프만-라 로슈 아게 인간 fcrn-결합 변형된 항체 및 사용 방법
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물

Also Published As

Publication number Publication date
CA3095295C (en) 2023-01-10
HUE062403T2 (hu) 2023-10-28
AU2015253915B2 (en) 2018-05-10
WO2015167293A1 (en) 2015-11-05
EP3137504A1 (en) 2017-03-08
IL248159B (en) 2021-02-28
AU2015253915A1 (en) 2016-12-01
EA201692192A1 (ru) 2017-04-28
ES2952583T3 (es) 2023-11-02
IL280613B (en) 2021-12-01
JP2017522043A (ja) 2017-08-10
KR101954906B1 (ko) 2019-03-08
MX2016014210A (es) 2017-05-01
CA3095295A1 (en) 2015-11-05
BR112016025319A2 (pt) 2017-12-12
SA516380194B1 (ar) 2020-10-14
US10544226B2 (en) 2020-01-28
US20240092913A1 (en) 2024-03-21
CN106459215B (zh) 2019-12-24
CA2945086C (en) 2020-12-29
MX2021005193A (es) 2021-09-08
DK3137504T3 (da) 2023-08-14
NZ726089A (en) 2017-12-22
EP3137504A4 (en) 2018-02-28
CN111138540B (zh) 2023-07-25
US20230235063A1 (en) 2023-07-27
KR20160145779A (ko) 2016-12-20
CN111138540A (zh) 2020-05-12
US20190135917A1 (en) 2019-05-09
CA2945086A1 (en) 2015-11-05
AU2018203582A1 (en) 2018-06-14
CN106459215A (zh) 2017-02-22
EP3137504B1 (en) 2023-05-10
KR101889466B1 (ko) 2018-08-21
PT3137504T (pt) 2023-08-18
JP6449441B2 (ja) 2019-01-09
US11613578B2 (en) 2023-03-28
US20250026835A1 (en) 2025-01-23
EP4241852A3 (en) 2023-11-15
US20170210801A1 (en) 2017-07-27
US20200109201A1 (en) 2020-04-09
DK3137504T5 (en) 2024-10-14
IL280613A (en) 2021-03-25
AU2018203582B2 (en) 2019-05-02
RS64542B1 (sr) 2023-09-29
EA038470B1 (ru) 2021-09-01
SG11201608208VA (en) 2016-11-29
MX382284B (es) 2025-03-13
KR20180093128A (ko) 2018-08-20
IL248159A0 (en) 2016-11-30
EP4241852A2 (en) 2023-09-13
FI3137504T3 (fi) 2023-08-07
PL3137504T3 (pl) 2023-10-16

Similar Documents

Publication Publication Date Title
NZ737666A (en) Antibody binding to fcrn for treating autoimmune diseases
ZA202109042B (en) Methods of reducing serum levels of fc-containing agents using fcrn antagonists
PH12017500819A1 (en) Cd3/cd38 t cell retargeting hetero-dimeric immunoglobulins and methods of their production
PH12020552178A1 (en) Anti-il36r antibodies
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
TW201613970A (en) Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JO3568B1 (ar) عوامل ربط cd123 واستخداماتها
PH12016501366A1 (en) Novel anti-baff antibodies
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2018009581A (es) Inmunoglobulina con fabs en tandem y sus usos.
MY175878A (en) Anti-il-17 antibodies, a method for producing and using thereof
PE20180499A1 (es) Anticuerpos de union a tau
TN2018000419A1 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof.
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
MX2018014937A (es) Anticuerpos anti-pd-1, un metodo de produccion y un metodo para su uso.
MX2016008667A (es) Inmunoglobulina con fab en tandem y usos de esta.
WO2016205551A3 (en) Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function
PH12016501937A1 (en) Method for improving solubility of protein and peptide by using immunoglobulin fc fragment linkage
MX2020010094A (es) Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
JOP20200161A1 (ar) أجسام مضادة أحادية النسيلة وطرق استخدامها
MY206214A (en) Monoclonal antibodies that bind specifically to human trbv9
MY205967A (en) Monoclonal antibodies against the beta chain region of human trbv9
MX2020002750A (es) Anticuerpo il-6r y fragmento de union a antigeno y uso medico.
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2020 BY CPA GLOBAL

Effective date: 20190314

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2021 BY FB RICE PTY LTD

Effective date: 20200205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2022 BY FB RICE PTY LTD

Effective date: 20210203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2023 BY FB RICE PTY LTD

Effective date: 20220208

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2024 BY FB RICE PTY LTD

Effective date: 20230203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2025 BY FB RICE PTY LTD

Effective date: 20240216

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 APR 2026 BY FB RICE PTY LTD

Effective date: 20250225